Watchlist Price Alert

Edgewise Therapeutics Inc... (EWTX)

NASDAQ: EWTX · Real-Time Price · USD

14.25

0.23 (1.64%)

At close: May 23, 2025, 3:59 PM

14.30

0.35%

After-hours: May 23, 2025, 05:18 PM EDT

1.64% (1D)

Bid	13.75
Market Cap	1.5B
Revenue (ttm)	n/a
Net Income (ttm)	-146.09M
EPS (ttm)	-1.55
PE Ratio (ttm)	-9.19
Forward PE	-7.35
Analyst	Buy

Ask	14.75
Volume	806,965
Avg. Volume (20D)	1,795,071
Open	14.05
Previous Close	14.02
Day's Range	13.75 - 14.30
52-Week Range	10.60 - 38.12
Beta	0.37

About EWTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol EWTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for EWTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

-22.9%

Edgewise Therapeutics shares are trading lower aft... Unlock content with Pro Subscription

5 months ago

+18.36%

Edgewise Therapeutics shares are trading higher after the company reported topline results from its Phase 2 CANYON trial of Sevasemten in individuals with Becker muscular dystrophy, with the trial meeting its primary endpoint.

News

6 days ago · zacks.com

All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy

Edgewise Therapeutics (EWTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 week ago · zacks.com

Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?

The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to a 174.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

3 weeks ago · fool.com

Why Edgewise Therapeutics Stock Popped This Week

On Thursday, an analyst launched coverage of Edgewise Therapeutics (EWTX 1.56%) stock, and the market took notice in a good way. On the back of his bullish view of the company, according to data compi...

1 month ago · 247wallst.com

These 5 Insiders Are Buying During Market Chaos

Market volatility has spiked since the beginning of April, due largely to uncertainty about inflation, interest rates, upcoming quarterly reports, and mostly the impact of tariffs and a global trade w...

1 month ago · zacks.com

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data

Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.

1 month ago · seekingalpha.com

Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On

The global hypertrophic cardiomyopathy market is expected to reach $1.35 billion by 2031. Despite a temporary stock drop due to adverse events and a $200 million stock offering, the long-term outlook ...

1 month ago · benzinga.com

Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study

Edgewise Therapeutics, Inc., EWTX on Wednesday reported topline data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic Cardiomyopa...

1 month ago · investors.com

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged

Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise. The post Why Edgewise Therapeutics And Cytokinetics Stocks J...

2 months ago · businesswire.com

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an i...

2 months ago · seekingalpha.com

Edgewise Therapeutics: More Expensive Now, But Much More Derisked

Edgewise Therapeutics' stock surged after strong midstage data from its Becker Muscular Dystrophy program, with the lead molecule sevasemten showing promising results. The GRAND CANYON trial, targetin...

Load More News